Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(83.3%)
N/A
1(16.7%)
6Total
Phase 1(5)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03265106Phase 1Unknown

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

Role: lead

NCT03941626Phase 1Unknown

Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

Role: lead

NCT03638193Not ApplicableUnknown

Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer

Role: lead

NCT03156101Phase 1Unknown

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

Role: lead

NCT04204161Phase 1Unknown

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Role: lead

NCT03638206Phase 1Unknown

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Role: lead

All 6 trials loaded